Blueprint Receives European Commission Approval for Mastocytosis Therapy

 -- AYVAKYT is the first approved therapy in the European Union designed to selectively target the KIT D816V mutation, the primary driver of disease --

-- Advanced Systemic Mastocytosis (AdvSM) is a debilitating disease characterized by damage across multiple organ systems, reduced overall survival and poor quality of life --

-- Initial commercial launch is planned for Germany immediately following the EC approval --

https://finance.yahoo.com/news/blueprint-medicines-ayvakyt-avapritinib-receives-141500977.html